Robert Stephen Hogg

Robert Stephen Hogg

Auto-generated profile, based on publicly available information

Robert Stephen Hogg

Faculty of Health Sciences, Simon Fraser University, Burnaby, BC V5A 1S6, Canada

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HSHasina Samji
Hasina Samji
ACAngela Cescon
Angela Cescon
RHRobert S. Hogg
Robert S. Hogg
SMSharada P. Modur
Sharada P. Modur
KAKeri N. Althoff
Keri N. Althoff
FIfor The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA
for The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA
Combination antiretroviral therapy (ART) has significantly increased survival among HIV-positive adults in the United States (U.S.) and Canada, but gains in life expectancy for this region have not been well characterized. We aim to estimate temporal changes in life expectancy among HIV-positive adults on ART from 2000–2007 in the U.S. and Canada. Participants were from the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), aged ≥20 years and on ART. Mortality rates were calculated using participants' person-time from January 1, 2000 or ART initiation until death, loss to follow-up, or administrative censoring December 31, 2007. Life expectancy at age 20, defined as the average number of additional years that a person of a specific age will live, provided the current age-specific mortality rates remain constant, was estimated using abridged life tables. The crude mortality rate was 19.8/1,000 person-years, among 22,937 individuals contributing 82,022 person-years and 1,622 deaths. Life expectancy increased from 36.1 [standard error (SE) 0.5] to 51.4 [SE 0.5] years from 2000–2002 to 2006–2007. Men and women had comparable life expectancies in all periods except the last (2006–2007). Life expectancy was lower for individuals with a history of injection drug use, non-whites, and in patients with baseline CD4 counts <350 cells/mm3. A 20-year-old HIV-positive adult on ART in the U.S. or Canada is expected to live into their early 70 s, a life expectancy approaching that of the general population. Differences by sex, race, HIV transmission risk group, and CD4 count remain.

1 July 2002 in The Lancet
Verified
Journal Article
Closed access
MEMatthias Egger
Matthias Egger
MMMargaret May
Margaret May
GCGeneviève Chêne
Geneviève Chêne
APAndrew N Phillips
Andrew N Phillips
BLBruno Ledergerber
Bruno Ledergerber
JSJonathan Ac Sterne
Jonathan Ac Sterne

30 April 2009 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
MKMari M. Kitahata
Mari M. Kitahata
SGStephen J. Gange
Stephen J. Gange
AAAlison G. Abraham
Alison G. Abraham
BMBarry Merriman
Barry Merriman
MSMichael S. Saag
Michael S. Saag
RMRichard D. Moore
Richard D. Moore
The optimal time for the initiation of antiretroviral therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection is uncertain. We conducted two parallel analyses involving a total of 17,517 asymptomatic patients with HIV infection in the United States and Canada who received medical care during the period from 1996 through 2005. None of the patients had undergone previous antiretroviral therapy. In each group, we stratified the patients according to the CD4+ count (351 to 500 cells per cubic millimeter or >500 cells per cubic millimeter) at the initiation of antiretroviral therapy. In each group, we compared the relative risk of death for patients who initiated therapy when the CD4+ count was above each of the two thresholds of interest (early-therapy group) with that of patients who deferred therapy until the CD4+ count fell below these thresholds (deferred-therapy group). In the first analysis, which involved 8362 patients, 2084 (25%) initiated therapy at a CD4+ count of 351 to 500 cells per cubic millimeter, and 6278 (75%) deferred therapy. After adjustment for calendar year, cohort of patients, and demographic and clinical characteristics, among patients in the deferred-therapy group there was an increase in the risk of death of 69%, as compared with that in the early-therapy group (relative risk in the deferred-therapy group, 1.69; 95% confidence interval [CI], 1.26 to 2.26; P<0.001). In the second analysis involving 9155 patients, 2220 (24%) initiated therapy at a CD4+ count of more than 500 cells per cubic millimeter and 6935 (76%) deferred therapy. Among patients in the deferred-therapy group, there was an increase in the risk of death of 94% (relative risk, 1.94; 95% CI, 1.37 to 2.79; P<0.001). The early initiation of antiretroviral therapy before the CD4+ count fell below two prespecified thresholds significantly improved survival, as compared with deferred therapy.

11 February 1998 in JAMA
Verified
Journal Article
Open access
PDF file
RHRobert S. Hogg
Robert S. Hogg
KHKatherine V. Heath
Katherine V. Heath
BYBenita Yip
Benita Yip
KCKevin J. P. Craib
Kevin J. P. Craib
MOMichael V. O'Shaughnessy
Michael V. O'Shaughnessy
JMJulio S. G. Montaner
Julio S. G. Montaner
ANTIRETROVIRAL therapy has been shown to prolong survival in persons with acquired immunodeficiency syndrome (AIDS) and those with intermediate-stage human immunodeficiency virus (HIV) infection.1-6 Between 1990 and 1995, didanosine and zalcitabine were increasingly used in combination with zidovudine. The available options for combination antiretroviral therapy expanded further when positive results were reported in clinical trials involving lamivudine and stavudine7-9 and, more recently, in trials involving protease inhibitors and nonnucleoside reverse transcriptase inhibitors.10-18 Recently, viral load–driven therapy has been adopted, as a growing body of evidence has established plasma viral load as a meaningful predictor of disease progression.19-21 Overall, these developments have resulted in significant changes to the therapeutic management of this disease22,23 and have led to a dramatic increase in the use of double- and, more recently, triple-combination antiretroviral therapy regimens among HIV-infected persons.

1 August 2010 in The Lancet
Verified
Journal Article
Closed access
JMJulio Sg Montaner
Julio Sg Montaner
VLViviane D Lima
Viviane D Lima
RBRolando Barrios
Rolando Barrios
BYBenita Yip
Benita Yip
EWEvan Wood
Evan Wood
PKPerry Kendall
Perry Kendall

28 November 2001 in JAMA
Verified
Journal Article
Open access
PDF file
RHRobert S. Hogg
Robert S. Hogg
BYBenita Yip
Benita Yip
KCKeith J. Chan
Keith J. Chan
EWEvan Wood
Evan Wood
KCKevin J. P. Craib
Kevin J. P. Craib
JMJulio S. G. Montaner
Julio S. G. Montaner
Triple-drug combination antiretroviral therapy has been shown to dramatically decrease morbidity and mortality in symptomatic and asymptomatic human immunodeficiency virus type 1 (HIV) infected individuals.1-3 As a result, triple-drug regimens have been widely adopted for the treatment of HIV infection starting in 1996.4-6 Recommendations for the initiation of antiretroviral therapy are largely based on CD4 T lymphocyte cell count and plasma HIV RNA levels. These thresholds have been selected based on the risk for disease progression in natural history and observational studies as well as randomized clinical trials.7-12 Rates of disease progression to acquired immunodeficiency syndrome (AIDS) or death for such thresholds in treated patients, however, have not been fully characterized. We, therefore, undertook our analysis in an attempt to characterize the rates of disease progression to AIDS or death as a function of baseline CD4 cell counts and HIV RNA levels in a population-based cohort of HIV-infected individuals initiating triple-drug antiretroviral therapy regimens. We further sought to identify a possible threshold at which the short-term clinical benefit derived from triple-drug regimens became compromised.